Long‐term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis

References

• Leung DY, Hanifin JM, Charlesworth EN et al, Disease management of atopic dermatitis: a practice parameter. Joint Task-Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immuno- logy, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol (1997) 79: 197–211.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Hwang ST, Udey MC, Allergic and immunologic diseases of the skin. J Allergy Clin Immunol (2003) 111: S560–70.
   PubMed Web of Science ®Google Scholar
• Williams HC, Is the prevalence of atopic dermatitis increasing? Clin Exp Dermatol (1992) 17: 385–91.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Honig PJ, Atopic dermatitis. Curr Opin Pediatr (1998) 10: 387–92.
   PubMedGoogle Scholar
• Williams H, Robertson G, Stewart A et al, Worldwide variations in the prevalence of symptoms of atopic eczema in the international study of asthma and allergies in childhood. J Allergy Clin Immunol (1999) 103: 125–38.
   Google Scholar
• Su JC, Kemp AS, Varigos GA, Nolan TM, Atopic eczema: its impact on the family and financial costs. Arch Dis Child (1997) 76: 159–62.
   PubMed Web of Science ®Google Scholar
• Hanifin JM, Tofte SJ, Update of therapy of atopic dermatitis. J Allergy Clin Immunol (1999) 104: S123–5.
   PubMed Web of Science ®Google Scholar
• Abeck D, Strom K, Optimal management of atopic dermatitis. Am J Clin Dermatol (2000) 1: 41–6.
   PubMedGoogle Scholar
• Hill CJ, Rosenberg A, Jr, Adverse effects from topical steroids. Cutis (1978) 21: 624–8.
   PubMed Web of Science ®Google Scholar
• Stoppolino G, Prisco F, Santinelli R et al, Potential hazards of topical steroids therapy. Am J Dis Child (1983) 137: 1130–1.
   Google Scholar
• Lewis-Jones S, Atopic dermatitis in childhood. Hosp Med (2001) 62: 136–43.
   PubMed Web of Science ®Google Scholar
• Queille C, Pommarede R, Saurat JH, Efficacy versus systemic side effects of six topical steroids in the treatment of atopic dermatitis of childhood. Pediatr Dermatol (1984) 1: 246–53.
   PubMedGoogle Scholar
• Turpeinen M, Salo OP, Leisti S, Effect of percutaneous absorption of hydrocortisone on adrenocortical respon- siveness in infants with severe skin disease. Br J Dermatol (1986) 115: 475–84.
   PubMed Web of Science ®Google Scholar
• Turpeinen M, Influence of age and severity of dermatitis on the percutaneous absorption of hydrocortisone in children. Br J Dermatol (1988) 118: 517–22.
   PubMed Web of Science ®Google Scholar
• Charman CR, Morris AD, Williams HC, Topical cortico- steroids phobia in patients with atopic eczema. Br J Dermatol (2000) 142: 931–6.
   PubMed Web of Science ®Google Scholar
• Paller A, McAllister RO, Doyle JJ, Jackson A, Perception of physicians and pediatric patients about atopic dermatitis, its impact and its treatment. Clin Pediatr (2002) 41: 323–32.
   PubMed Web of Science ®Google Scholar
• Fischer G, Compliance problems in paediatric atopic eczema. Australas J Dermatol (1996) 37: 10–13.
   PubMedGoogle Scholar
• Grassberger M, Baumruker T, Enz A et al, A novel anti- inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol (1999) 141: 264–73.
   PubMed Web of Science ®Google Scholar
• Stuetz A, Grassberger M, Meingassner JG, Pimecrolimus (Elidel, SDZ ASM 981) – preclinical pharmacologic profile and skin selectivity. Semin Cutan Med Surg (2001) 20: 233–41.
   PubMed Web of Science ®Google Scholar
• Wellington K, Jarvis B, Topical pimecrolimus. A review of its clinical potential in the management of atopic dermatitis. Drugs (2002) 62: 817–40.
   PubMed Web of Science ®Google Scholar
• Bos JD, Kapsenberg ML, Smitt JH, Pathogenesis of atopic eczema. Lancet (1994) 343: 1338–41.
   PubMed Web of Science ®Google Scholar
• Meingassener JG, Kowalsky E, Schwendinger H et al, Pimecrolimus does not affect Langerhans cells in murine epidermis. Br J Dermatol (2003) 149: 853–7.
   PubMed Web of Science ®Google Scholar
• Kalthoff F, Meingassner JG, Chung J et al, Pimecrolimus is more cell-selective than corticosteroids: in vivo and in vitro data. J Eur Acad Dermatol Venereol (2002) 16 (suppl 1): 257–8 (abstract).
   Google Scholar
• Queille-Roussel C, Paul C, Duteil L et al, The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol (2001) 144: 507–13.
   PubMed Web of Science ®Google Scholar
• Van Leent EJM, Ebelin M-E, Burtin P et al, Low systemic exposure after repeated topical application of pimecro- limus (Elidel1, SDZ ASM 981) in patients with atopical dermatitis. Dermatology (2002) 204: 63–8.
   Google Scholar
• Meingassner JG, Grassberger M, Fahrngruber H et al, A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol (1997) 137: 568–76.
   PubMed Web of Science ®Google Scholar
• Van Leent EJM, Gra¨ ber M, Thurston M et al, Effective- ness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol (1998) 134: 805–9.
   PubMedGoogle Scholar
• Luger T, van Leent EJM, Gra¨ ber M et al, SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol (2001) 144: 788–94.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Lucky AW, Boguniewicz M et al, Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol (2002) 46: 495–504.
   PubMed Web of Science ®Google Scholar
• Ho VC, Gupta A, Kaufmann R et al, Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J Pediatr (2003) 142: 155–62.
   PubMed Web of Science ®Google Scholar
• Whalley D, Huels J, McKenna SP, van Assche D, The benefit of pimecrolimus (Elidel, SDZ ASM 981) on parents’ quality of life in the treatment of pediatric atopic dermatitis. Pediatrics (2002) 110: 1133–6.
   PubMed Web of Science ®Google Scholar
• Kapp A, Papp K, Bingham A et al, Long-term manage- ment of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol (2002) 110: 277–84.
   PubMed Web of Science ®Google Scholar
• Wahn U, Bos JD, Goodfield M et al, Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics (2002) 110: 1–8.
   PubMedGoogle Scholar
• Meurer M, Fo¨lster-Holst R, Wozel G et al, Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology (2002) 205: 271–7.
   PubMed Web of Science ®Google Scholar
• Williams HC, Burney PG, Pembroke AC, Hay RJ, The UK Working Party’s diagnostic criteria for atopic dermatitis. III. Independent hospital validation. Br J Dermatol (1994) 134: 805–9. Hanifin JM, Rajka G, Diagnostic features of atopic dermatitis. Acta Derm Venereol (1980) 92 (suppl): 44–7.
   Google Scholar
• Rajka G, Langeland T, Grading the severity of atopic dermatitis. Acta Derm Venereol (1989) 144 (suppl): 13–14.
   Google Scholar
• Hanifin JM, Thurston M, Omoto M et al, The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol (2001) 10: 11–18.
   PubMed Web of Science ®Google Scholar
• Hoare C, Li Wan Po A, Williams H, Systematic review of treatments for atopic dermatitis. Health Technol Assess (2000) 4: 1–191.
   Google Scholar
• Hauser C, Prins C, Lacour M, The role of infectious agents. In: Leung DYM, ed. Atopic Dermatitis: From Pathogenesis to Treatment. RG Landes Co: Austin, 1996: 67–112.
   Google Scholar
• Reitamo S, Wollenberg A, Scho¨pf E et al, Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. Arch Dermatol (2000) 136: 999–1006.
   PubMed Web of Science ®Google Scholar
• Nassif A, Chan SC, Storrs FJ et al, Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol (1994) 130: 1402–7.
   PubMedGoogle Scholar
• Pincelli C, Fantini F, Massimi P et al, Neuropeptides in skin from patients with atopic dermatitis: an immuno- histochemical study. Br J Dermatol (1990) 122: 745–50.
   PubMed Web of Science ®Google Scholar
• Sugiura H, Omoto M, Hirota Y et al, Density and fine structure of peripheral nerves in various skin lesions of atopic dermatitis. Arch Dermatol Res (1997) 289: 125–31.
   PubMed Web of Science ®Google Scholar
• Reitamo S, Rustin M, Ruzicka T et al, Efficacy and safety of tacrolimus ointment compared with that of hydro- cortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol (2002) 109: 547–55.
   PubMed Web of Science ®Google Scholar
• Drake L, Dinehart SM, Farmer ER et al, Guidelines of care for the use of topical glucocorticosteroids. J Am Acad Dermatol (1996) 35: 615–19.
   PubMed Web of Science ®Google Scholar
• Fukaya M, Why do patients with atopic dermatitis refuse to apply topical corticosteroids? Dermatology (2000) 201: 242–5.
   PubMed Web of Science ®Google Scholar